Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Panbela Therapeutics (PBLA)
OTHER OTC:PBLA
RESEARCH TOOLSreports
Holding PBLA?
Track your performance easily
PBLA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.30 - $38.00
Previous Close$0.36
Volume13.72K
Average Volume (3M)8.55K
Market Cap
$1.67M
Enterprise Value$5.80M
Total Cash (Recent Filing)$59.00K
Total Debt (Recent Filing)$4.19M
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Nov 14, 2024EPS Estimate
-$1.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-84.77
Shares Outstanding4,854,861
10 Day Avg. Volume4,259
30 Day Avg. Volume8,555
Standard Deviation0.33
R-Squared0.02
Alpha-0.13
Financial Highlights & Ratios
Price to Book (P/B)-0.16
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Panbela Therapeutics News
PremiumPre-Earnings
Is PBLA a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 3 ASPIRE clinical trial continues without modifications, with enrollment on track for completion.
CollaborationsThe Phase 1 study evaluating Ivospemin in platinum-resistant ovarian cancer is set to open in collaboration with Johns Hopkins University.
Regulatory ApprovalFDA announced the approval of IWILFIN (eflornithine) for reducing relapse risk in adult and pediatric patients with high-risk neuroblastoma.
Bears Say
Analyst RatingAnalyst downgrades the rating to Neutral from Buy due to cash and listing risks.
Cash FlowCurrent cash burn rate is expected to jump to ~$7 million/quarter as enrollment increases in Panbela's trials.
Stock DilutionPanbela is considering implementing a reverse stock split in the near future to meet the exchange's listing requirements.
---
Ownership Overview
8.73%
Insiders
― Other Institutional Investors
91.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PBLA FAQ
What was Panbela Therapeutics’s price range in the past 12 months?
Panbela Therapeutics lowest stock price was $0.30 and its highest was $38.00 in the past 12 months.
What is Panbela Therapeutics’s market cap?
Currently, no data Available
When is Panbela Therapeutics’s upcoming earnings report date?
Panbela Therapeutics’s upcoming earnings report date is Nov 14, 2024 which is in 4 days.
How were Panbela Therapeutics’s earnings last quarter?
Panbela Therapeutics released its earnings results on Aug 13, 2024. The company reported -$1.47 earnings per share for the quarter, beating the consensus estimate of -$2.07 by $0.6.
Is Panbela Therapeutics overvalued?
According to Wall Street analysts Panbela Therapeutics’s price is currently Overvalued.
Does Panbela Therapeutics pay dividends?
Panbela Therapeutics does not currently pay dividends.
What is Panbela Therapeutics’s EPS estimate?
Panbela Therapeutics’s EPS estimate is -$1.63.
How many shares outstanding does Panbela Therapeutics have?
Panbela Therapeutics has 4,854,861 shares outstanding.
What happened to Panbela Therapeutics’s price movement after its last earnings report?
Panbela Therapeutics reported an EPS of -$1.47 in its last earnings report, beating expectations of -$2.07. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Panbela Therapeutics?
Currently, no hedge funds are holding shares in PBLA
---
Panbela Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-97.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-51.85%
Trailing 12-Months
Company Description
Panbela Therapeutics
Sun BioPharma Inc. is a clinical-stage drug development company, which engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The company was founded by Michael Cullen and Thomas Neenan on September 21, 2011 and is headquartered in Waconia, MN.
---
PBLA Earnings Call
Q2 2024
0:00 / 0:00
---
PBLA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering PBLA
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-99.10%
reiterated a buy rating 11 months ago
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -99.10% per trade.
---